https://www.selleckchem.com/pr....oducts/gusacitinib.h
Currently, the standard treatment modality for patients with acute ischemic stroke (AIS) presenting with isolated M2 occlusions is not specific. We therefore assessed the difference in treatment outcomes for patients with isolated M2 occlusions. We retrospectively analyzed consecutive patients with AIS presenting with isolated M2 occlusions from October 1, 2018, to June 30, 2020. Patients were divided into 3 groups based on the treatments they received no reperfusion therapy (NRT), intravenous thrombolysis treatment (IVT), and endov
Aimer
Commentaire
Partagez
